PDCD1 and small cell lung carcinoma: It is an inspiring research direction that biomarkers for predicting the efficacy of immunotherapy can be used to screen out patients who may really benefit from immunotherapy, especially when the benefits of programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) ICIs in ES-SCLC are limited in the whole population.